VD
Endocannabinoid Biology1 Active Trial

Vincenzo Di Marzo, PhD

Canada Excellence Research Chair in Microbiome-Endocannabinoidome Interactions; Director, Institut sur la Nutrition et les Aliments Fonctionnels

Université Laval · Quebec City, Canada

h-index 112
82,000+ citations
720+ publications
1 active trial

Biography

Vincenzo Di Marzo is one of the world's most prolific and influential cannabinoid scientists, with over 700 publications and more than 80,000 citations. Formerly at the Italian National Research Council in Naples, he relocated to Université Laval in 2018 to lead a Canada Excellence Research Chair program. Di Marzo's laboratory discovered the "endocannabinoidome" — the expanded family of endocannabinoid-like lipid mediators — and has been central to understanding how the endocannabinoid system regulates metabolism, appetite, gut function, and the microbiome. His work on the role of endocannabinoids in obesity and metabolic syndrome has opened new therapeutic avenues for cannabinoid-based medicines targeting metabolic disease.

Key Contributions

  • 1Coined and defined the "endocannabinoidome" — the expanded family of endocannabinoid-related lipid mediators
  • 2Elucidated the biosynthesis and degradation pathways of anandamide and 2-AG
  • 3Demonstrated that the endocannabinoid system regulates energy balance and appetite ("the endocannabinoid system and the control of food intake")
  • 4Established the gut microbiome as a regulator of endocannabinoid tone
  • 5Discovered that obesity is associated with overactivation of the peripheral endocannabinoid system
  • 6Identified FAAH and MAGL as therapeutic targets for endocannabinoid-based medicines

Selected Publications

The Endocannabinoid System and Its Therapeutic Exploitation

5,600 citations

Nature Reviews Drug Discovery · 2004

Comprehensive review of the endocannabinoid system as a therapeutic target, covering CB1/CB2 receptors, endocannabinoid biosynthesis/degradation, and therapeutic applications in pain, neurodegeneration, cancer, and metabolic disease. One of the most-cited reviews in cannabinoid pharmacology.

DOI: 10.1038/nrd1495

Gut Microbiota Controls Adipose Tissue Expansion, Gut Barrier and Glucose Metabolism: Novel Insights into Molecular Targets and Interventions Using Prebiotics

890 citations

British Journal of Pharmacology · 2015

Demonstrated that gut microbiota modulates endocannabinoid tone in adipose tissue and gut epithelium, linking microbiome composition to metabolic syndrome via endocannabinoid signaling. Established the gut microbiome-endocannabinoidome axis.

DOI: 10.1111/bph.12908

Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action

2,400 citations

Trends in Neurosciences · 1998

Landmark review establishing the endocannabinoid system as a retrograde neuromodulatory system, with anandamide and 2-AG acting as "on-demand" lipid messengers that suppress presynaptic neurotransmitter release. Defined the canonical mechanism of endocannabinoid signaling.

DOI: 10.1016/S0166-2236(97)01200-0
View all publications on PubMed